Includes Total Omnipod ® Revenue Growth of 26% ACTON, Mass. --(BUSINESS WIRE)--Aug. 6, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial
ACTON, Mass. --(BUSINESS WIRE)--Jun. 29, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the second quarter of 2020 on
ACTON, Mass. --(BUSINESS WIRE)--Jun. 24, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced its corporate headquarters and manufacturing facility in Acton, MA ,
ACTON, Mass. --(BUSINESS WIRE)--Jun. 11, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced its robust schedule of events for the American Diabetes Association
ACTON, Mass. --(BUSINESS WIRE)--Jun. 5, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced it has resumed its pivotal study of Omnipod, Powered by Horizon™, the
ACTON, Mass. --(BUSINESS WIRE)--May 28, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at two upcoming virtual investor conferences: The Piper
ACTON, Mass. --(BUSINESS WIRE)--May 12, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the pricing of its $500 million common stock registered
ACTON, Mass. --(BUSINESS WIRE)--May 12, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), a global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced that it plans to make an offering of $500 million of its
ACTON, Mass. --(BUSINESS WIRE)--May 8, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet ), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that management will present at two upcoming investor conferences: The BofA Securities
Includes Total Omnipod Revenue Growth of 33% ACTON, Mass. --(BUSINESS WIRE)--May 7, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System), today announced financial
ACTON, Mass --(BUSINESS WIRE)--Apr. 16, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced an expansion of its U.S. financial assistance program for current
ACTON, Mass. --(BUSINESS WIRE)--Apr. 6, 2020-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced plans to release its financial results for the first quarter of 2020 on
Product Innovation Award Further Validates Omnipod as a Consumer Preferred Solution ACTON, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® DASH Insulin Management System (Omnipod DASH ™
ACTON, Mass. --(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) ( Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System, today announced that it plans to pause the pivotal study of the Omnipod Horizon™ Automated Glucose
